STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner

This publication has 34 references indexed in Scilit:

• The STATs of cancer — new molecular targets come of age
  Nature Reviews Cancer, 2004
• 5-Fluorouracil: mechanisms of action and clinical strategies
  Nature Reviews Cancer, 2003
• MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
  Blood, 2003
• Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro
  Molecular Cancer, 2003
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
  Cancer Cell, 2002
• Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease
  Oncogene, 2002
• Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
  2002
• Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
  2002
• The role of mitogen-activated protein (MAP) kinase in breast cancer
  The Journal of Steroid Biochemistry and Molecular Biology, 2002
• Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3
  Oncogene, 2000